Share

January 2022; 9 (1) ArticleOpen Access

Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis

Markus Bock, Falk Steffen, Frauke Zipp, Stefan Bittner
First published November 11, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001102
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1324

Share

Article Information

vol. 9 no. 1 e1102
DOI: 
https://doi.org/10.1212/NXI.0000000000001102
PubMed: 
34764215
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 13, 2021
  • Accepted in final form September 21, 2021
  • First Published November 11, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Markus Bock, MD,
    2. Falk Steffen, MD (f.steffen{at}uni-mainz.de),
    3. Frauke Zipp, MD (zipp{at}uni-mainz.de) and
    4. Stefan Bittner, MD (bittner{at}uni-mainz.de)
  1. Markus Bock, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Schär AG Burgstall, Italy

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Myelin Projekt e.V., Germany 2) Familie Ernst Wendt Stiftung Köln, Germany

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Falk Steffen, MD (f.steffen{at}uni-mainz.de),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Frauke Zipp, MD (zipp{at}uni-mainz.de) and
    4. Scientific Advisory Boards:

    1. (1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche

    Editorial Boards:

    1. (1) Brain, Associate Editor, 2021- (2) Science Translational Medicine, Advisor, 2021-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme

    Research Support, Government Entities:

    1. (1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2024 (2) DFG CRC1080, PI, 2013-2024 (3) BMBF HaltMS, PI, 2020-2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Progressive MS Alliance, BRAVEinMS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Stefan Bittner, MD (bittner{at}uni-mainz.de)
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. S. B. has received funding for travel expenses for attending meetings from Novartis and Merck Serono and honoraria from Biogen Idec, BMS, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Research Council (DFG, CRC-TR-128)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.B., F.S., F.Z., S.B.), Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz; Institute of Biochemistry (M.B.), University Medicine Berlin—Charité, Germany; and Experimental & Clinical Research Center (ECRC) A Joint Cooperation of Charité Medical Faculty and Max-Delbrueck-Center for Molecular Medicine (MDC) (M.B.).
  1. Correspondence
    Dr. Bock markus.bock{at}posteo.de
View Full Text

Article usage

Article usage: November 2021 to August 2023

AbstractFullPdfSource
Nov 2021201070279Highwire
Dec 202115451100Highwire
Jan 20221941292Highwire
Feb 20221215849Highwire
Mar 20221315577Highwire
Apr 2022817260Highwire
May 2022711537Highwire
Jun 20221313245Highwire
Jul 20221811827Highwire
Aug 20221513731Highwire
Sep 20221111643Highwire
Oct 2022814045Highwire
Nov 20221216081Highwire
Dec 20221512440Highwire
Jan 20235722235Highwire
Feb 2023108237Highwire
Mar 2023117655Highwire
Apr 2023106037Highwire
May 2023156745Highwire
Jun 20231010137Highwire
Jul 2023159848Highwire
Aug 202377324Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me